Keryx Biopharmaceuticals (NASDAQ:KERX) saw a large growth in short interest in November. As of November 30th, there was short interest totalling 21,658,433 shares, a growth of 6.9% from the November 15th total of 20,254,558 shares. Approximately 18.3% of the company’s stock are sold short. Based on an average trading volume of 1,893,740 shares, the short-interest ratio is currently 11.4 days.

KERX has been the subject of several analyst reports. Zacks Investment Research upgraded shares of Keryx Biopharmaceuticals from a “sell” rating to a “hold” rating in a report on Monday, October 16th. ValuEngine cut shares of Keryx Biopharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Friday, November 10th. Stifel Nicolaus lowered their price target on shares of Keryx Biopharmaceuticals from $7.00 to $5.00 and set a “hold” rating for the company in a report on Wednesday, November 8th. Finally, BidaskClub upgraded shares of Keryx Biopharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, August 16th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and one has assigned a buy rating to the company. Keryx Biopharmaceuticals presently has an average rating of “Hold” and a consensus target price of $7.35.

Keryx Biopharmaceuticals (KERX) opened at $4.73 on Thursday. Keryx Biopharmaceuticals has a twelve month low of $4.33 and a twelve month high of $8.38. The company has a debt-to-equity ratio of 13.95, a quick ratio of 3.76 and a current ratio of 4.46.

Keryx Biopharmaceuticals (NASDAQ:KERX) last issued its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($0.03). Keryx Biopharmaceuticals had a negative net margin of 323.92% and a negative return on equity of 10,954.62%. The company had revenue of $15.00 million during the quarter, compared to analyst estimates of $18.88 million. During the same quarter in the previous year, the company posted ($0.39) EPS. The company’s quarterly revenue was up 138.1% on a year-over-year basis. equities analysts expect that Keryx Biopharmaceuticals will post -1.36 EPS for the current fiscal year.

Institutional investors have recently modified their holdings of the company. Fox Run Management L.L.C. acquired a new position in shares of Keryx Biopharmaceuticals in the 3rd quarter valued at $101,000. Engineers Gate Manager LP acquired a new position in shares of Keryx Biopharmaceuticals in the 3rd quarter valued at $102,000. Principal Financial Group Inc. boosted its holdings in shares of Keryx Biopharmaceuticals by 4.2% in the 2nd quarter. Principal Financial Group Inc. now owns 14,759 shares of the biopharmaceutical company’s stock valued at $107,000 after buying an additional 590 shares in the last quarter. Raymond James Financial Services Advisors Inc. boosted its holdings in shares of Keryx Biopharmaceuticals by 51.8% in the 2nd quarter. Raymond James Financial Services Advisors Inc. now owns 16,495 shares of the biopharmaceutical company’s stock valued at $119,000 after buying an additional 5,628 shares in the last quarter. Finally, Cubist Systematic Strategies LLC acquired a new position in shares of Keryx Biopharmaceuticals in the 2nd quarter valued at $183,000. Institutional investors and hedge funds own 64.83% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Short Interest in Keryx Biopharmaceuticals (KERX) Rises By 6.9%” was originally published by American Banking News and is owned by of American Banking News. If you are accessing this story on another domain, it was stolen and republished in violation of United States & international copyright & trademark laws. The correct version of this story can be accessed at https://www.americanbankingnews.com/2017/12/14/short-interest-in-keryx-biopharmaceuticals-kerx-rises-by-6-9.html.

About Keryx Biopharmaceuticals

Keryx Biopharmaceuticals, Inc is a biopharmaceutical company focused on the development of medicines for people with renal disease. The Company is engaged in the manufacture, development and commercialization of products for use in treating human diseases. Its marketed product, Auryxia (ferric citrate), which is an orally available, absorbable, iron-based medicine is approved in the United States for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis.

Receive News & Ratings for Keryx Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keryx Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.